Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Oncogenic osteomalacia 2Nevus, Sebaceous of Jadassohn 2

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × burosumab × Clear all
NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT02722798 2022-09-06

A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Kyowa Kirin Co., Ltd.

Phase 2 Completed
14 enrolled

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡